← All trials
NCT03321734
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2018
- Primary completion
- May 31, 2022
- Completion date
- May 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 220
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Georgetown UniversityLead sponsor
- National Institutes of Health (NIH)Collaborator
- United States ArmyCollaborator
- University of PennsylvaniaCollaborator
- American SIDS InstituteCollaborator
- Boston UniversityCollaborator
- Harvard UniversityCollaborator
- Dartmouth UniversityCollaborator
- Georgetown UniversityReponsible party - principal investigator
- Johns Hopkins UniversityCollaborator
- University of MassachusettsCollaborator
- Children's National Medical CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.